Young patient’s decade-long C. diff battle highlights shifting infection risks and the value of community support

Key points

• Hatch first developed gastrointestinal symptoms at age 19, but C. diff was not diagnosed until 2015 after a gastroenterologist connected her history of frequent antibiotic use to her condition.
• She underwent three FMTs over the years; the first provided temporary relief, but she later contracted C. diff again after a dentist prescribed antibiotics for wisdom tooth removal.
• During the COVID-19 pandemic, Hatch suffered severe opportunistic infections, dropping to 94 pounds, which led to her third FMT in 2021.
• In 2025, an immunologist diagnosed her with a primary immunodeficiency disorder, explaining her susceptibility to infections; she switched from broad-spectrum antibiotics to IVIG, which has prevented further C. diff episodes.
• Hatch’s public sharing of her story has helped others seek diagnoses, demonstrating the impact of patient communities on health outcomes.

Background

C. diff infections have historically been associated with older patients in healthcare settings, but recent data indicates a significant shift. A July 2026 study in the American Journal of Infection Control reported a 59% increase in C. diff cases among people aged 18 to 24 between 2014 and 2024. While hospital rates have decreased due to better antimicrobial stewardship, community cases are rising. Experts attribute this to persistent spores in environments like public bathrooms and homes, as well as widespread gut microbiome dysbiosis caused by diet and antibiotic use. Approximately 30,000 patients die annually from C. diff in the US, with nearly half a million infections occurring each year.

Why it matters

The case of Minnie Hatch highlights a critical gap in medical recognition for younger patients with chronic infections. Her decade-long struggle, marked by misdiagnosis and self-doubt, illustrates how C. diff can mimic other conditions and recur due to underlying immune issues. As C. diff migrates from hospitals to the community, understanding risk factors like primary immunodeficiency and the role of patient advocacy becomes essential for improving outcomes and reducing the burden of this toxic colitis.

What to watch

Hatch is currently stable on IVIG therapy and has not experienced a C. diff recurrence. She continues to advocate for others through the Peggy Lillis Foundation, aiming to reduce isolation and accelerate diagnoses for those suffering from similar chronic infections. Medical professionals are increasingly monitoring younger populations for C. diff, particularly those with a history of antibiotic use or unexplained recurrent infections.